Welcome to MyElanco!

The MyElanco website is intended for Veterinary professionals, SQPs / RAMAs and Professional Keepers of Animals. By continuing to MyElanco you are confirming your professional status as one of the above.

Pet owners please visit our website MyPet&I.

Skip to main content


Zenrelia gets dogs back to normal

Back to normal

Zenrelia (ilunocitinib) gets nearly 50% more itchy dogs back to normal than Apoquel® (oclacitinib)1††

Zenrelia once daily dosing

Once-daily dosing

Simple, consistent dosing from the start2

Zenrelia calendar icon

Itch control

Zenrelia delivers 24-hour itch relief1,3

Zenrelia safety icon

Safety profile

Safety profile comparable to Apoquel1

Zenrelia's price helps make the benefits of JAK inhibitors for long-term itch relief accessible to more dogs.‡

Value

Zenrelia’s price helps make the benefits of JAK inhibitors for long-term itch relief accessible to more dogs.

*Referenceable claims in digital and social copy can be found on this page. Full reference list below.

Based on list price of Zenrelia vs other licensed JAK inhibitors for dogs as of 07/25.

†† 77% of dogs treated with Zenrelia achieved PVAS <2 by day 112 compared to 53% of dogs treated with Apoquel. A ‘normal’ itch score is considered to be comparable to that of a healthy, non-allergic dog (PVAS <2)1

  1. Forster S et al. Vet Dermatol. 2025 Apr;36(2):165-176.
  2. Zenrelia™ Summary of Product Characteristics.
  3. Unpublished data: Owner Pruritus Assessment (PVAS) form.